Melanoma: how the first mRNA vaccine against cancer works
Merck and Moderna's mRNA vaccine, tailored to patients' genetic profiles, reduced melanoma recurrence by 42% in a phase 3 trial when combined with immunotherapy. The vaccine, called intismeran, targets neoantigens in tumor cells, training the immune system to attack them. The study involved 1137 patients, with 82% of those receiving the vaccine and immunotherapy surviving without recurrence after two years, compared to 70% with immunotherapy alone.
How this was made
The 30-second read
Why it matters
The data could expand the therapeutic scope of mRNA technology and influence oncology stock valuations.
Market read
Breakthrough trial results may drive short‑term price moves in Merck and Moderna and shape investor sentiment toward mRNA oncology assets.
What to watch
Regulatory timeline extends to 2027; early data may not translate into near‑term sales.
Background
First public disclosure of Phase 3 results for an mRNA melanoma vaccine co‑developed by Merck and Moderna, presented at the ESMO congress.
Ticker impact
Merck co‑developed the mRNA melanoma vaccine that showed a 42% reduction in recurrence in a Phase 3 trial.
likely upward pressure as investors price in the new efficacy data
Phase 3 results are material for a large pharma; market typically reacts positively to such breakthroughs.
Moderna partnered with Merck on the mRNA melanoma vaccine that cut recurrences by 42% in Phase 3.
potential upside as investors view the data as a new growth avenue
Moderna's core business is mRNA; a successful cancer vaccine could diversify revenue and lift valuation.
Market effects
Strengthens the oncology mRNA sub‑sector and may spur competitor R&D activity.
European biotech investors may see heightened interest after the ESMO presentation.
Adds a new potential cancer therapy to the global mRNA pipeline landscape.
Counterpoint
High development cost ($200k per patient) could limit adoption and pressure margins.
Key entities
- companyMerck
Pharmaceutical giant co‑developer of the vaccine.
- companyModerna
mRNA platform leader partnering on the vaccine.
